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To the Editor-in-Chief: 
In February 2020, the World Health Organization 
officially named the disease caused by the new 
corona virus as COVID-19. For COVID-19 patients, 
there are usually four phases of the disease. The 
first one is virus reproduction phase. The second 
phase is accompanied with mild symptoms and 
usually includes flu-like symptoms. The third 
phase is associated with the development of acute 
respiratory distress syndrome (ARDS) and is 
characterized by its symptoms. The fourth phase 
is associated with high fever, systemic 
inflammatory responses, especially in the lungs, 
and eventual respiratory failure (1). COVID-19 is 
associated with upregulations of inflammatory 
cytokines. In the acute phase of COVID-19, the 
function of TCD4+ cells are impaired and the 
production of interferon-gamma (IFN-γ) and 
Tumor Necrosis Factor-alpha (TNF-α) in these 
cells is reduced. With impaired immune function, 
virus replication continues, and damaged lung 
cells induce excessive inflammatory responses 
and overproduction of inflammatory cytokines 
such as TNF-α, IL-1β, and IL-6 from immune cells 
(2). This eventually induce cytokine storm with 
systemic inflammatory responses and end organ 
damage. The level of inflammatory cytokines such 
as IL-1β, IL-6 and IL-10 in COVID-19 patients has 
been reported to be higher in COVID-19 patients 
admitted in ICU (3). 
The lack of effective treatment for the severe 
infection caused by COVID-19 has led scientists 
and physicians to repurpose popular medications 
that are indicated for other similar conditions. No 
effective modality to successful management of 
this viral disease has yet been identified. 
Immunosuppressive and anti-inflammatory drugs 
have been suggested for acute patients with 
cytokine storms and severe lung involvement.  
Recently, due to the anti-inflammatory effects of 
selective serotonin reuptake inhibitors (SSRIs), 
their therapeutic effects have been proposed for 
COVID-19 patients. This group of drugs are usually 
prescribed to treat depressive disorders. SSRIs 
have been shown to reduce inflammation and the 
expression of inflammatory cytokines such as 
TNF⍺ and IL-1β (4). The decrease in inflammatory 
cytokines such as IL-1β and TNF-α in the cerebral 
tissue has been shown as a result of sertraline 
administration (5), indicating the anti-
inflammatory effects of this drug. In another 
study, Fluvoxamine could lower IL-1β, IL-6, and 
TNFα expression in the striatum in depressed 
mice (6). Much attention is paid to sertraline due 
to its very low anticholinergic activity which is 
especially desirable for the elderly with coronary 
heart diseases. Moreover, the anti-inflammatory 
properties of this compound is attributed to 
prevention of the expression of pro-inflammatory 
cytokines. 
Recently, it was demonstrated that treatment of 
patients with major depression with SSRIs could 
reduce the expression of inflammatory cytokines, 
such as IL-10, TNF-α, and IL-6 in these patients 
(7). The expression of these inflammatory 
mediators increase in critically ill COVID-19 
patients. Therefore, the use of this class of 
medications in the management of COVID-19 
patients could be considered, especially for acute 
patients with cytokine storms. In a recently 
published study, the use of antidepressants SSRI 
and paroxetine and SNRI venlafaxine in 
hospitalized patients due to COVID-19 reduced the 
risk of intubation and death (8). This therapeutic 
effect on COVID-19 could be attributed to the 
inhibition of acid sphingomyelinase activity, which 
prevents epithelial cell from being infection by 
SARS-CoV2.  
It has also been suggested that S1A (σ-1- receptor) 
agonists can prevent cytokine storms in severe 
COVID-19 (9). SSRIs, especially fluvoxamine and 
to a lesser extent sertraline have a moderate to 
high affinity for this receptor. Antidepressants are 
associated with decreased plasma levels of pro-
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inflammatory cytokines which elevate in COVID-
19. Furthermore, the antiviral activity of some 
antidepressants such as fluoxetine has been 
reported in COVID-19 patients. In a randomized 
clinical trial on adult outpatients with COVID-19, 
administration of 100 mg of fluvoxamine reduced 
the likelihood of clinical deterioration over 15 
days (10). This has been attributed to the high 
affinity of fluvoxamine for S1R, which reduces the 
inflammatory responses.  
It seems that SSRIs are potential candidates for 
COVID-19 due to their anti-inflammatory 
properties. Future clinical studies will determine 
the exact role of this class of medications in 
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